CAPP3
Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers (CaPP3 Israel)A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention Programme (CaPP3).
Population: adult | Intervention type: therapeutic medicinal product
